|
WO2020081398A1
|
|
Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer
|
|
WO2019200238A1
|
|
Combinations including a cpg-c type oligonucleotide and a histone deacetylase inhibitor for treating cancer
|
|
EP3710059A1
|
|
Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
|
|
US2019062329A1
|
|
Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
|
|
EP3538513A1
|
|
Toll-like receptor antagonist compounds and methods of use
|
|
CA3020873A1
|
|
Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
|
|
US2017087245A1
|
|
Methods and compositions for eliciting an immune response against hepatitis B virus
|
|
EP3590518A1
|
|
Polynucleotide toll-like receptor 9 agonists for treating cancer of the lung
|
|
CN107567335A
|
|
Branched and linear Chimeric compounds, polynucleotides, their Use and preparation method
|
|
US2015132293A1
|
|
Immunostimulatory sequence oligonucleotides and methods of using the same
|
|
US2015252363A1
|
|
Human toll-like receptor inhibitors and methods of use thereof
|
|
AU2013203815A1
|
|
Methods of treatment using TLR7 and/or TLR9 inhibitors
|
|
AU2013203855A1
|
|
Human toll-like receptor inhibitors and methods of use thereof
|
|
US2014094504A1
|
|
Human toll-like receptor inhibitors and methods of use thereof
|
|
WO2012135549A2
|
|
Tlr8 transgenic animals
|
|
AU2011268211A1
|
|
Methods of treatment using TLR7 and/or TLR9 inhibitors
|
|
AU2011365013A1
|
|
Methods and compositions for eliciting an immune response against hepatitis B virus
|
|
WO2011159328A1
|
|
Methods of treatment using tlr7 and/or tlr9 inhibitors
|
|
WO2010002940A2
|
|
Heterogeneous synthesis of multivalent chimeric immunomodulatory compounds using platform based molecules
|
|
EP2300102A2
|
|
Immunostimulatory sequences containing CpG for use in the treatment of allergic rhinitis
|
